Shares of GSK PLC GSK rose 1.11% to £13.62 Thursday, on what proved to be an all-around favorable trading session for the ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK -4178116 (GSK4178116A) is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous ...

Drugmaker GSK said, a stamp has been released by India Post to commemorate its 100 years in India. The ₹5 denomination stamp ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

On Friday, GSK plc (GSK) stock saw a decline, ending the day at $33.47 which represents a decrease of $-0.48 or -1.41% from the prior close of $33.95. The stock opened at $33.98 and touched a low of ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK PLC GSK shares dropped 1.58% to £13.40 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.44% to 8,223.98. Supported by ...